The binding ability of these deletant proteins to AD5-10, a mouse anti-human DR5 monoclonal antibody, was evaluated by immunoblotting and ELISA.
利用蛋白免疫印迹及ELISA技术研究重组蛋白与小鼠抗人DR5单克隆抗体AD5-10的结合情况。
2
The Ad5-TRAIL gene therapy for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.